Form 4: AN2 Therapeutics Insider Sells Shares for Tax Withholding

Sarah Joanne Williams, Principal Accounting Officer at AN2 Therapeutics, Inc., reported a sale of 265 common shares to cover tax withholding obligations related to vesting Restricted Stock Units.

Summary

• Sarah Joanne Williams, Principal Accounting Officer at AN2 Therapeutics, Inc., sold 265 shares of common stock on May 29, 2026.
• The sale was conducted to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs).
• The transaction price was $4.43 per share.
• Following this transaction, Ms. Williams beneficially owns 66,583 shares of common stock.
• The filing also details the vesting schedules for various RSU grants, with vesting occurring over four years from January 1, 2025, January 1, 2026, and May 28, 2024, respectively.
• A total of 3,766 shares were sold to cover taxes, and 814 shares were sold on the open market from aggregate RSU issuances.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction is a standard procedure for covering tax liabilities on vested equity awards and does not indicate a change in the reporting person's fundamental view of the company's prospects.

Positives

• The sale was a pre-planned transaction to cover tax obligations, indicating responsible financial management by the reporting person.
• The reporting person continues to hold a significant number of shares (66,583) after the transaction.
• The RSU grants have structured vesting schedules, aligning employee incentives with long-term company performance.

Negatives

• The sale of shares, even for tax purposes, represents a reduction in the reporting person's direct ownership.

Risks

• Vesting of RSUs is subject to the Reporting Person's continuous service through each applicable vesting date, implying a risk of forfeiture if service is not maintained.
• The company's stock price performance could impact the value of the remaining RSUs and future equity compensation.

Future Outlook

The filing details ongoing vesting schedules for Restricted Stock Units, indicating continued equity-based compensation tied to employee service over the next several years.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding are common events, particularly following RSU vesting. The structure of these sales, as detailed in this Form 4, is typical for managing equity compensation obligations in the biotechnology sector.

Stakeholder Impact

• Shareholders: The sale of 265 shares is a minor transaction and is unlikely to have a significant impact on the stock price. The continued holding of a substantial number of shares by a key officer is a positive signal.
• Employees: The RSU vesting schedules indicate ongoing incentive programs designed to retain and motivate employees.
• Management: The transaction demonstrates adherence to tax obligations related to equity compensation.

Next Steps

• Continued vesting of RSUs according to the specified schedules, subject to continued service.
• Potential future sales by reporting persons to cover tax obligations as RSUs vest.

Key Dates

Keywords

AN2 Therapeutics, ANTX, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Beneficial Ownership, Principal Accounting Officer